Nervous Disorder TRIZ Cases

A ketogenic composition induces physiologically acceptable ketosis to restore chromatin balance and ameliorate neurogenesis deficits in Kabuki syndrome.

Triheptanoin metabolism bypasses glucose deficits to reduce amyloid-beta and restore cognitive function.

Fraxinus rhynchophylla extract treats depression by increasing serotonin and BDNF while reducing cortisol side effects.

Low-dose roflumilast improves memory and executive function while avoiding adverse events.

Intranasal caspase inhibitor and cell-penetrating peptide conjugates extend the therapeutic window for ischemic injury treatment.

Composite antioxidant system protects fresh marine omega-3 oil from oxidation while enhancing absorption to treat Alzheimer's symptoms.

Nasal naltrexone formulations reverse opioid overdose complications through rapid mucosal absorption without intravenous risks.

Converting oil-like asenapine base into a crystalline phosphate salt resolves low yield and purity trade-offs during industrial purification.

A LKKTET peptide agent modulates actin polymerization to promote healing in neuro-muscular tissues.

Substituted aminothiol structures enable oral administration of radioprotectors, resolving intravenous toxicity and limited organ protection constraints.

Annexin A5 enhances cerebral blood flow and glucose uptake to mitigate lesion size and morbidity.

A human monoclonal antibody binds specifically to delta-like ligand 4 to block receptor interaction.

A peptide composition inhibits Toll-like Receptor 2 activation by MyD88 to reduce microglial inflammation.

An adeno-associated virus vector transports anti-neoplastic immunoglobulin genes directly to the central nervous system.

High-loading sodium oxybate tablets dissolve rapidly to match oral solution bioavailability while solving hygroscopic handling challenges.

Adding concentrated complex lipids like GM3 and GD3 to low-fat dairy bases increases brain weight and body growth without raising adiposity levels.

A beverage formulation combines epigallocatechin gallate with nicotinamide ribose to stimulate endogenous NAD+ production.

Analyzing hsa-miR-30b-5p dysregulation resolves early detection gaps, reducing diagnostic complexity and improving clinical outcomes.

A chimeric antigen receptor integrates catalytic intracellular signaling domains to enhance immune cell activation.

Modified circular permuted caspase-2 cleaves N-terminal tags from fusion proteins.

Phenyl isothiocyanate agents inhibit unregulated microglia phagocytic activity to prevent neuronal cell death in neurodegenerative disorders.

Oral miglustat inhibits trehalase to prevent trehalose hydrolysis, resolving low brain bioavailability from rapid metabolism.

Analyzing plasma lipidomic profiles detects memory impairment risk by comparing deviations from normal values, avoiding invasive cerebrospinal fluid procedures.

Mesenchymal stem cells address drug-resistant epilepsy by inducing neuroprotection and reducing neuroinflammatory status in patients.

Antisense oligonucleotides targeting Grik2 mRNA reduce GluK2 protein expression via RNA interference mechanisms.

Thiol-based conjugation prevents oligomerization and truncation, ensuring intact hapten structure for high antibody specificity.

Alpha-7 nicotinic agonists mediate emergence from general anesthesia, reducing unpredictable recovery times and complications.

Ethanol extract of Hibiscus syriacus protects nerve cells and reduces inflammatory factors in animal models.

Exosomal miR-23b-3p replaces complex genetic screening to enable non-invasive early diagnosis of Alzheimer's disease.

Block copolymer micelles transport drugs through nasal mucosa to the spinal cord, bypassing systemic barriers that limit therapeutic concentration.

Truncated SOD1 peptides inhibit toxic aggregate formation to delay ALS progression.

A multi-component pharmaceutical composition targets mu-opioid, alpha-adrenergic, and cholinergic receptors simultaneously to reverse opioid overdose effects.

Site-specific HER2 antibody drug conjugates achieve uniform drug ratios by segmenting the conjugation process.

Cuminaldehyde activates TRPA1 receptors to provoke swallowing, replacing irritating agonists that cause burning sensations and aspiration risks.

Segmented IL-17A epitope vaccination reduces inflammation without immunosuppression side effects like infections or myelosuppression.

Targeting PIG3 activity slows disease progression and alleviates motor symptoms like tremor and rigidity in GBA or LRRK2-associated Parkinson's cases.

A TRPV1 agonist prodrug formulation delivers sustained analgesia through metabolic conversion to an active compound.

A botanical extract mixture increases GABA content through synergistic enzymatic conversion.

A probiotic composition containing Bifidobacterium longum subsp. infantis modifies intestinal flora to improve mental health dysfunction.

Covalent fatty acid amide conjugates merge omega-3 fatty acids with biologically active amines to enhance intracellular delivery efficiency.

Segmented therapeutic agents combine truncated serine proteases with targeting ligands to achieve high cytotoxicity while minimizing inadvertent toxicity.

Engineered anti-CD47 antibodies bind tumor CD47 to block SIRPα, inducing phagocytosis while sparing normal cells.

Developing specific salt forms resolves the contradiction between enhanced bioavailability and complex crystalline form selection.

Modified antibody sequences inhibit nerve growth factor without cross-reacting with neurotrophin-3, resolving specificity contradictions.

Identifying mitochondrial protein signatures across multiple matrices resolves reproducibility issues and improves diagnostic accuracy.

Subcutaneous iduronate-2-sulfatase administration resolves intravenous infusion burdens while maintaining therapeutic efficacy.

Defined transcription factors reprogram somatic cells to pluripotency, resolving ethical concerns from nuclear transfer and improving efficiency.